ReviewLeukemia2024
Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.
Review in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- Quality of care index for acute lymphoblastic leukaemia at global, regional, and national levels: a systematic analysis of the global burden of disease from 1990 to 2021.Journal of global health · 2026Article
- Taking High-Tech to the Field: Leukemia Diagnosis in Pediatric Mexican Patients from Vulnerable and Remote Regions.Diagnostics (Basel, Switzerland) · 2026Article
- Precision Pediatric Cancer Nanomedicine: Advancing Personalized Nano Therapies to Reduce Non-Communicable Diseases Through AI-Driven 3D-Printed Drugs.International journal of nanomedicine · 2026Review
- Molecular diagnostics in paediatric oncology in Latin America: findings from the Latin America Regional Advisory Committee (RAC LATAM) regional assessment.Ecancermedicalscience · 2026Article
- Article
- Priority setting for improved leukemia management and research in South Africa: a modified Delphi study.Cancer causes & control : CCC · 2025Article
- Review
- Clinical characteristics and outcomes of paediatric acute lymphoblastic leukaemia in a tertiary hospital in Tanzania: a single-centre observational study.Tropical medicine and health · 2025Article
- Analysis of global trends in acute lymphoblastic leukemia in children aged 0-5 years from 1990 to 2021.Frontiers in pediatrics · 2025Article
- Global, regional, and national burden of children and adolescents with acute lymphoblastic leukemia from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.Frontiers in public health · 2025Article
- Chemosensitizing effect of apigenin on T-ALL cell therapy.Frontiers in pharmacology · 2025Article
- Enhancing outcomes of childhood acute lymphoblastic leukemia in workplace diversity in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.Annals of hematology · 2024Article
- Disparities in incidence and mortality of pediatric acute lymphoblastic leukemia across countries with different incomes.Leukemia · 2024Article
- Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead.Cureus · 2024Review
- Therapeutic controversies over use of antioxidant supplements during cancer treatment: a scoping review.Frontiers in nutrition · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
The survival rate of children and adolescents with acute lymphoblastic leukemia (ALL), the most common pediatric cancer, has improved significantly in high-income countries (HICs), serving as an excellent example of how humans can overcome catastrophic diseases. However, the outcomes in children with ALL in low- and middle-income countries (LMICs), where approximately 80% of the global population live, are suboptimal because of limited access to diagnostic procedures, chemotherapeutic agents, supportive care, and financial assistance. Although the implementation of therapeutic strategies in resource-limited countries could theoretically follow the same path of improvement as modeled in HICs, intensification of chemotherapy may simply result in increased toxicities. With the advent of genetic diagnosis, molecular targeted therapy, and immunotherapy, the management of ALL is changing dramatically in HICs. Multidisciplinary collaborations between institutions in LMICs and HICs will provide access to strategies that are suitable for institutions in LMICs, enabling them to minimize toxicities while improving outcomes. This article summarizes important aspects of the diagnosis and treatment of pediatric ALL that were mostly developed in HICs but that can be realistically implemented by institutions in countries with limited resources through resource-adapted multidisciplinary collaborations.
Indexed as
Identifiers
38762553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.